UNSPSC 51202207: Dexrazoxane hydrochloride

This classification denotes a metal chelator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5346058Q7S. European Medicines Agency schedules Dexrazoxane hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01631MIG. Dexrazoxane hydrochloride generally arises in the molecular formula C11H16N4O4.CLH. The term 'dexrazoxane hydrochloride' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule dexrazoxane hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, DEXRAZOXANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Dexrazoxane hydrochloride bears US NLM identifiers UMLS ID C0982118 and NCI Concept Code C66945. SMILES: C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2.CL.

UNSPSC 51202207 Dexrazoxane hydrochloride is a Commodity code, but the recent state and local contract opportunities tagged under it show little alignment with the code's pharmaceutical scope. The City of Tucson's RFP for athletic training services to the Fire and Police Departments, the City of Tampa's ITB for medical aid supplies (antiseptic sprays, hydrogen peroxide, aspirin, bandages, first-aid kits, emergency blankets), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs do not involve dexrazoxane hydrochloride or cardiotoxicity mitigation agents. The athletic training solicitation focuses on injury prevention, fitness evaluation, and rehabilitation services; the medical aid supplies procurement targets commodity-level first-aid and general-purpose medical items; and the Texas RFI concerns pharmacy benefit program structure and manufacturer contracting relationships. None of these opportunities represent the kind of specialized pharmaceutical procurement that would typically flow under this Commodity code.

The geographic spread of recent activity spans Arizona, Florida, and Texas, but the opportunities appear to reflect either miscoding or sourcing of broader medical and health service contracts that fall outside the dexrazoxane hydrochloride commodity scope. Issuing bodies include municipal fire departments, a city procurement office, and a state health agency. Without recent opportunities that actually solicit dexrazoxane hydrochloride or chemotherapy-related cardioprotective agents, this code shows limited signal for vendors focused on oncology pharmaceuticals or similar specialty products in state and local procurement.